PMID- 22397368
OWN - NLM
STAT- MEDLINE
DCOM- 20120606
LR  - 20240508
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 11
DP  - 2012 Mar 7
TI  - Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose 
      tolerance test are associated with the presence of coronary artery diseases in 
      patients with prediabetes.
PG  - 21
LID - 10.1186/1475-2840-11-21 [doi]
AB  - BACKGROUND: Meta-analysis has demonstrated an exponential relationship between 
      2-hr postchallenge hyperglycemia and coronary artery disease (CAD). Pulsatile 
      hyperglycemia can acutely increase proinflammatory cytokines by oxidative stress. 
      We hypothesized that postchallenge proinflammatory and nitrosative responses 
      after 75 g oral glucose tolerance tests (75 g-OGTT) might be associated with CAD 
      in patients without previously recognized type 2 diabetes mellitus (T2DM). 
      METHODS: Serial changes of plasma glucose (PG), tumor necrosis factor-alpha 
      (TNF-alpha), interleukin-6 (IL-6) and nitrotyrosine levels were analyzed during 75 
      g-OGTT in 120 patients (81 male; age 62 +/- 11 years) before coronary angiography. 
      Patients were classified as normal (NGT; 42%), impaired (IGT; 34%) and diabetic 
      (T2DM; 24%) glucose tolerance by 75 g-OGTT. RESULTS: Postchallenge hyperglycemia 
      elicited TNF-alpha, IL-6 and nitrotyrosine levels time-dependently, and 2-hr median 
      levels of TNF-alpha (7.1 versus 6.4 pg/ml; P < 0.05) and nitrotyrosine (1.01 versus 
      0.83 mumol/l; P < 0.05), but not IL-6 or PG, were significantly higher in patients 
      with CAD in either IGT or T2DM groups. After adjusting risk factors and glucose 
      tolerance status, 2-hr nitrotyrosine in highest quartiles (OR: 3.1, P < 0.05) 
      remained an independent predictor of CAD by logistic regression analysis. 
      CONCLUSIONS: These results highlight postchallenge proinflammatory and 
      nitrosative responses by 75 g-OGTT, rather than hyperglycemia per se, are 
      associated with CAD in patients without previous recognized diabetes.
FAU - Chu, Chih-Sheng
AU  - Chu CS
AD  - Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
FAU - Lee, Kun-Tai
AU  - Lee KT
FAU - Cheng, Kai-Hong
AU  - Cheng KH
FAU - Lee, Min-Yi
AU  - Lee MY
FAU - Kuo, Hsuan-Fu
AU  - Kuo HF
FAU - Lin, Tsung-Hsien
AU  - Lin TH
FAU - Su, Ho-Ming
AU  - Su HM
FAU - Voon, Wen-Chol
AU  - Voon WC
FAU - Sheu, Sheng-Hsiung
AU  - Sheu SH
FAU - Lai, Wen-Ter
AU  - Lai WT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120307
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (IL6 protein, human)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Coronary Angiography
MH  - Coronary Artery Disease/blood/diagnosis/*etiology
MH  - Diabetes Complications/blood/diagnosis/*etiology
MH  - Diabetes Mellitus, Type 2/blood/*complications/diagnosis
MH  - Female
MH  - *Glucose Tolerance Test
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Interleukin-6/blood
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prediabetic State/blood/*complications/diagnosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Taiwan
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/*blood
MH  - Tyrosine/*analogs & derivatives/blood
PMC - PMC3316140
EDAT- 2012/03/09 06:00
MHDA- 2012/06/07 06:00
PMCR- 2012/03/07
CRDT- 2012/03/09 06:00
PHST- 2011/11/14 00:00 [received]
PHST- 2012/03/07 00:00 [accepted]
PHST- 2012/03/09 06:00 [entrez]
PHST- 2012/03/09 06:00 [pubmed]
PHST- 2012/06/07 06:00 [medline]
PHST- 2012/03/07 00:00 [pmc-release]
AID - 1475-2840-11-21 [pii]
AID - 10.1186/1475-2840-11-21 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2012 Mar 7;11:21. doi: 10.1186/1475-2840-11-21.